Target Name: RBFOX1
NCBI ID: G54715
Other Name(s): RNA binding protein fox-1 homolog 1 isoform 1 | FOX-1 | RBFOX1 variant 3 | Ataxin-2-binding protein 1 | RNA binding protein fox-1 homolog 1 (isoform 2) | RNA binding protein fox-1 homolog 1 isoform gamma | Ataxin 2-binding protein 1 | RNA binding protein, fox-1 homolog (C. elegans) 1, transcript variant 4 | RNA binding protein, fox-1 homolog 1 | RNA binding protein fox-1 homolog 1 isoform X4 | RNA binding fox-1 homolog 1, transcript variant 6 | RNA binding protein, fox-1 homolog (C. elegans) 1, transcript variant X1 | Hexaribonucleotide binding protein 1 isoform beta | HRNBP1 | RBFOX1 variant 5 | 2BP1 | RNA binding protein fox-1 homolog 1 | RBFOX1 variant 4 | RNA binding protein fox-1 homolog 1 (isoform 3) | ataxin 2-binding protein 1 | RNA binding protein fox-1 homolog 1 (isoform 5) | RNA binding fox-1 homolog 1 | RBFOX1 variant 1 | FOX1 | RNA binding fox-1 homolog 1, transcript variant 5 | RNA binding protein fox-1 homolog 1 (isoform 1) | A2BP | RNA binding fox-1 homolog 1, transcript variant 2 | Hexaribonucleotide binding protein 1 isoform alpha | RNA binding protein, fox-1 homolog (C. elegans) 1, transcript variant 7 | RNA binding fox-1 homolog 1, transcript variant 3 | Hexaribonucleotide-binding protein 1 | RNA binding protein fox-1 homolog 1 (isoform 6) | A2BP1 | A2BP1 variant gamma | RFOX1_HUMAN | RNA binding fox-1 homolog 1, transcript variant 1 | RNA binding protein fox-1 homolog 1 (isoform 4) | Fox-1-like RNA-binding protein 1 | RBFOX1 variant X1 | RNA binding protein fox-1 homolog 1 (isoform X1) | RBFOX1 variant 7 | Fox-1 homolog A | hexaribonucleotide-binding protein 1 | RBFOX1 variant 2 | fox-1-like RNA-binding protein 1 | RBFOX1 variant 6 | Hexaribonucleotide binding protein 1 | fox-1 homolog A

RBFOX1: A Potential Drug Target and Biomarker

Ribofoxinuracil (RBFOX1) is a drug that is currently in clinical trials for the treatment of various cancers, including colorectal cancer. It works by inhibiting the activity of the enzyme topoisomerase II, which is responsible for the DNA replication process in cancer cells. This inhibition results in the DNA double-strand breaks, which can lead to the eventual death of the cancer cells.

RBFOX1 is a small molecule inhibitor of topoisomerase II, which is expressed in most tissues and cells in the body. It is currently being investigated as a potential drug target for cancer treatment. By inhibiting the activity of topoisomerase II, RBFOX1 has the potential to disrupt the replication of DNA in cancer cells, leading to the death of the cells.

In addition to its potential as a cancer drug, RBFOX1 has also been identified as a potential biomarker for the disease. The DNA double-strand breaks that result from the inhibition of topoisomerase II can be detected in the blood or urine of cancer patients. This can be used as a marker for the presence of cancer cells, as well as for tracking the effectiveness of cancer treatments.

The identification of RBFOX1 as a potential drug target and biomarker has significant implications for the development of cancer treatments. Cancer treatments are often limited by the ability to target specific cancer cells, as well as the potential side effects of the treatments. By inhibiting the activity of topoisomerase II, RBFOX1 has the potential to be a more effective cancer treatment than traditional chemotherapy or radiation therapy.

In addition to its potential as a cancer drug, RBFOX1 has also been identified as a potential biomarker for the disease. The DNA double-strand breaks that result from the inhibition of topoisomerase II can be detected in the blood or urine of cancer patients. This can be used as a marker for the presence of cancer cells, as well as for tracking the effectiveness of cancer treatments.

The identification of RBFOX1 as a potential drug target and biomarker has significant implications for the development of cancer treatments. Cancer treatments are often limited by the ability to target specific cancer cells, as well as the potential side effects of the treatments. By inhibiting the activity of topoisomerase II, RBFOX1 has the potential to be a more effective cancer treatment than traditional chemotherapy or radiation therapy.

In conclusion, RBFOX1 is a small molecule inhibitor of topoisomerase II that has the potential to be a cancer drug and a potential biomarker for the disease. Further research is needed to fully understand its potential as a cancer treatment and to develop safe and effective methods for its use.

Protein Name: RNA Binding Fox-1 Homolog 1

Functions: RNA-binding protein that regulates alternative splicing events by binding to 5'-UGCAUGU-3' elements. Regulates alternative splicing of tissue-specific exons and of differentially spliced exons during erythropoiesis

More Common Targets

RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1